PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPd0332991
Pd0332991
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
440 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C507211839687294
CarcinomaD002277—C80.038—1416
Ovarian neoplasmsD010051EFO_0003893C5668—1—14
Renal cell carcinomaD002292EFO_0000376—27—1—8
Endometrial neoplasmsD016889EFO_0004230—45—1—8
Thyroid neoplasmsD013964EFO_0003841——1—1—2
Therapeutic equivalencyD013810—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8028253—653
Neoplasm metastasisD009362EFO_0009708—769—121
Triple negative breast neoplasmsD064726——773—620
SarcomaD012509——471—113
Male breast neoplasmsD018567——244—313
Squamous cell carcinoma of head and neckD000077195——471——10
Squamous cell carcinomaD002294———51—16
RecurrenceD012008——411——6
Breast diseasesD001941—N60-N65222—26
Squamous cell neoplasmsD018307——121—14
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175—C34.9075——212
Pancreatic neoplasmsD010190EFO_0003860C2574———10
Non-small-cell lung carcinomaD002289——57———9
MelanomaD008545——35——28
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.071———7
Colorectal neoplasmsD015179——44———7
Head and neck neoplasmsD006258——45———7
LymphomaD008223—C85.944———7
Kidney neoplasmsD007680EFO_0003865C6427———7
Prostatic neoplasmsD011471—C6133———6
Show 85 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———18————18
Myelodysplastic syndromesD009190—D462————2
Erbb-2 genesD018734——2————2
SyndromeD013577——2————2
ThromboembolismD013923——1———12
Drug therapyD004358——2————2
InflammationD007249MP_0001845—2————2
ImmunotherapyD007167——2————2
Myeloproliferative disordersD009196—D47.11————1
Primary myelofibrosisD055728—D47.41————1
Show 41 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RadiotherapyD011878——————11
NeutropeniaD009503—D70————11
Bone diseasesD001847—M89.9————11
Venous thromboembolismD054556EFO_0004286I74————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name—
INN—
Description
—
Classification
Unknown
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL ID—
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use